Jietao Lin

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 6

Top Venues

Integrative cancer therapies

Journal of oncology

Trials

Guangzhou University of Chinese Medicine

Guangzhou University of Chinese Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Guangzhou University of Chinese Medicine Jul 01 2011

China

Doctor :: The First Affiliated Hospital

Education History

Guangzhou University of Chinese Medicine Jul 01 2016

China

PHD :: The First Affiliated Hospital

Guangzhou University of Chinese Medicine Jul 01 2004 - Jun 30 2011

China

MSC :: The First Affiliated Hospital

Publications

Wenmin Chen, Jietao Lin, Ting Yang, Ze Xin Zhang, Lanting Tao, Zhiwei Xiao, Hanrui Chen, Xiangjun Qi, Lingling Sun, Yang Cao, Li-Zhu Lin
Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study. Integrative cancer therapies 22 (2023)
Wenmin Chen, Jietao Lin, Ting Yang, Ze Xin Zhang, Lanting Tao, Zhiwei Xiao, Hanrui Chen, Xiangjun Qi, Lingling Sun, Yang Cao, Li-Zhu Lin
Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study. Integrative cancer therapies 22 (2023)
Jietao Lin, Lingling Sun, Hanrui Chen, Wenmin Chen, Zexin Zhang, Yang Cao, Li-Zhu Lin
Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort). Integrative cancer therapies 22 (2023)
Wenmin Chen, Jietao Lin, Ting Yang, Ze Xin Zhang, Lanting Tao, Zhiwei Xiao, Hanrui Chen, Xiangjun Qi, Lingling Sun, Yang Cao, Li-Zhu Lin
Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study. Integrative cancer therapies 22 (2023)
Chong-Kai Fang, Yue Huang, Chuyao Chen, Duo-Rui Nie, Jietao Lin, Zhiwei Xiao, Sai-Mei Li, Silin Liu, Rui Luo, Hongtong Lin, Chong Zhong, Xuewu Huang, Lizhu Lin
The Prognostic Value of Serum Apolipoprotein A-I Level and Neutrophil-to-Lymphocyte Ratio in Colorectal Cancer Liver Metastasis. Journal of oncology 2022 (2022)
Zhiwei Xiao, Leihao Hu, Jietao Lin, Liming Lu, Xuewu Huang, Xiaoshu Zhu, Chiahshean Teo, Li-Zhu Lin
Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial. Trials 21 (1) (2020)

Jietao Lin.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jietao Lin